Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Jimenez, Rosa H ^a   Boylan, Joan M ^a   Lee, Ju Seog ^b   Francesconi, Mirko ^c   Castellani, Gastone ^c   Sanders, Jennifer A ^a   Gruppuso, Philip A ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; INITIATION FACTOR 4E BINDING PROTEIN 1; RAPAMYCIN; S6 KINASE; ANTINEOPLASTIC ANTIBIOTIC; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN SERINE THREONINE KINASE; RNA; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; DOWN REGULATION; DRUG RESPONSE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IC 50; MICROARRAY ANALYSIS; NONHUMAN; PROTEIN SYNTHESIS; RAT; ANIMAL; CELL LINE; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION PROFILING; LIVER; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

RATTUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL LINE, TUMOR; CYCLIN E; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RNA; SIROLIMUS;

EID: 70350536552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007373     Document Type: Article

References (48)

1. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, et al. (1993) Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73: 585-596.
2. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E (2000) Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev 14: 2689-2694.
3. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/ eIF4E. Genes Dev 16: 1472-1487.
4. Gingras AC, Raught B, Sonenberg N (2004) mTOR signaling to translation. Curr Top Microbiol Immunol 279: 169-197.
5. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
6. Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361.
7. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
8. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
9. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483-510.
10. Chiang GG, Abraham RT (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13: 433-442.
11. Hosoi H, Dilling MB, Liu LN, Danks JK, Shikata T, et al. (1998) Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54: 815-824.
12. Huang S, Bjornsti MA, Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2: 222-232.
13. Choo AY, Blenis J (2009) Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8: 567-572.
14. Treiber G (2009) mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 9: 247-261.
15. Baba HA, Wohlschlaeger J, Cicinnati VR, Hilgard P, Lang H, et al. (2009) Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 29: 399-405.
16. Zhou L, Huang Y, Li J, Wang Z (2009) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol [Epub ahead of print].
17. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, et al. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972-1983.
18. Wang W, Jia WD, Xu GL, Wang ZH, Li JS, et al. (2008) Antitumoral Activity of Rapamycin Mediated Through Inhibition of HIF-1a and VEGF in Hepatocellular Carcinoma. Dig Dis Sci 54: 2128-2136.
19. Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, et al. (2009) Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 135: 715-722.
20. Heuer M, Benko T, Cicinnati VR, Kaiser GM, Sotiropoulos GC, et al. (2009) Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines. Transplant Proc 41: 359-365.
21. Boylan JM, Anand P, Gruppuso PA (2001) Ribosomal protein S6 phosphorylation and function during late gestation liver development in the rat. J Biol Chem 276: 44457-44463.
22. Pitot HC, Peraino C, Morse PA Jr, Potter VR (1964) Hepatomas in tissue culture compared with adapting liver in vivo. Natl Cancer Inst Monogr 13: 229-245.
23. Tsao MS, Grisham JW, Nelson KG (1985) Clonal analysis of tumorigenicity and paratumorigenic phenotypes in rat liver epithelial cells chemically transformed in vitro. Cancer Res 45: 5139-5144.
24. Campbell WA, Sah DE, Medina MM, Albina JE, Coleman WB, et al. (2000) TA1/ LAT1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. J Biol Chem 275: 5347-5354.
25. Tsao MS, Smith JD, Nelson KG, Grisham JW (1984) A diploid epithelial cell line from normal adult rat liver with phenotypic properties of 'oval' cells. Exp Cell Res 154: 38-52.
26. Lee LW, Tsao MS, Grisham JW, Smith GJ (1989) Emergence of neoplastic transformants spontaneously or after exposure to N-methyl-N'-nitro-N-nitrosoguanidine in populations of rat liver epithelial cells cultured under selective and nonselective conditions. Am J Pathol 135: 63-71.
27. Hixson DC, McEntiré KD, Obrink B (1985) Alterations in the expression of a hepatocyte cell adhesion molecule by transplantable rat hepatocellular carcinomas. Cancer Res 45: 3742-3749.
28. Hixson DC, Brown J, McBride AC, Affigne S (2000) Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface -reactive monoclonal antibodies. Exp Mol Pathol 68: 152-169.
29. Curran TRJ, Bahner RIJ, Oh W, Gruppuso PA (1993) Mitogen-independent DNA synthesis by fetal rat hepatocytes in primary culture. Exp Cell Res 209: 53-57.
30. Gruppuso PA, Boylan JM, Anand P, Bienieki TC (2005) Effects of maternal starvation on hepatocyte proliferation in the late gestation fetal rat. Pediatr Res 57: 185-191.
31. Sarsour EH, Agarwal M, Pandita TK, Oberley LW, Goswami PC (2005) Manganese superoxide dismutase protects the proliferative capacity of confluent normal human fibroblasts. J Biol Chem 280: 18033-18041.
32. Boylan JM, Gruppuso PA (2005) D-type cyclins and G1 progression during liver development in the rat. Biochem Biophys Res Commun 330: 722-730.
33. Inoki K, Ouyang H, Li Y, Guan KL (2005) Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69: 79-10
34. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
35. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
36. Francesconi M, Remondini D, Neretti N, Sedivy JM, Cooper LN, et al. (2008) Reconstructing networks of pathways via significance analysis of their intersections. BMC Bioinformatics 9 Suppl 4: S9.
37. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
38. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang, J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032.
39. Panasyuk G, Nemazanyy I, Zhyvoloup A, Filonenko V, Davies D, et al. (2009) The mTORβ splicing isoform promotes cell proliferation and tumorigenesis. J Biol Chem [Epub ahead of print].
40. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN (2006) AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66: 5618-5623.
41. Jiang Y-P, Ballou LM, Lin RZ (2001) Rapamycin-insensitive regulation of 4EBP1 in regenerating rat liver. J Biol Chem 276: 10943-10951.
42. Anand P, Gruppuso PA (2006) Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation. J Nutr 136: 27-33.
43. Dever TE (2002) Gene-specific regulation by general translation factors. Cell 108: 545-556.
44. Xie MW, Jin F, Hwang H, Hwang S, Anand V, et al. (2005) Insights into TOR function and rapamycin response: chemical genomic profiling by using a high-density cell array method. Proc Natl Acad Sci U S A 102: 7215-7220.
45. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
46. Mayer C, Zhao J, Yuan X, Grummt I (2004) mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 18: 423-434.
47. Mayer C, Grummt I (2006) Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 25: 6384-6391.
48. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J (2003) IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 163: 931-936.